Skip to main content

Table 4 Diagnostic value of CA125 combined with NLR and/or PLR in the diagnosis of EOTs

From: Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors

Variable

Groups

AUC

Cut-off

P-value

Sensitivity (%)

Specificity (%)

Comparison of AUC

Groups

P-value

Benign vs. malignant

CA125 + NLR

0.9540

0.3679

< 0.0001

90.63

99.35

a vs. b

0.1785

CA125 + PLR

0.9692

0.4404

< 0.0001

90.63

98.71

b vs. c

0.1217

CA125 + NLR + PLR

0.9793

0.2401

< 0.0001

93.75

96.77

a vs. c

0.0491

Benign vs. borderline

CA125 + NLR

0.8856

0.3132

< 0.0001

71.43

93.55

a vs. b

0.0932

CA125 + PLR

0.9144

0.2715

< 0.0001

80.95

91.61

b vs. c

0.1981

CA125 + NLR + PLR

0.9287

0.2699

< 0.0001

85.71

90.97

a vs. c

0.0037

Borderline vs. malignant

CA125 + NLR

0.7676

0.4350

< 0.0001

70.31

79.37

a vs. b

0.6527

CA125 + PLR

0.7584

0.4406

< 0.0001

73.44

73.02

b vs. c

0.5866

CA125 + NLR + PLR

0.7617

0.4129

< 0.0001

78.13

68.25

a vs. c

0.7360

  1. CA125+NLR
  2. CA125+PLR
  3. CA125+NLR+PLR